J-TEC applies for osteoarthritis treatment using autologous chondrocyte tissue

J-TEC, as subsidiary of Fujifilm, has submitted a clinical trial plan for the treatment of osteoarthrosis by its autologous chondrocyte tissue product “Jack”. Jack acquired manufacturing and marketing authorization in 2012 for traumatic cartilage defect in knee joint or transdermal osteochondritis. It was Japan’s first regenerative medicine product in the orthopedics field, covered by insurance since 2013. The company plans clinical trials at 10 institutes including Hiroshima and Shimane University.

J-TEC news release, July 20, 2018

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny